Authors: FINEMAN MS ORGAN K KOLTERMAN OG

Citation: Ms. Fineman et al., THE HUMAN AMYLIN ANALOG PRAMLINTIDE SUPPRESSED GLUCAGON-SECRETION IN PATIENTS WITH TYPE-2 DIABETES, Diabetologia, 41, 1998, pp. 653-653

Authors: RATNER R LEVETAN C SHOENFELD S ORGAN K KOLTERMAN O

Citation: R. Ratner et al., PRAMLINTIDE THERAPY IN THE TREATMENT OF INSULIN-REQUIRING TYPE-2 DIABETES - RESULTS OF A 1-YEAR PLACEBO-CONTROLLED TRIAL, Diabetes, 47, 1998, pp. 341-341

Authors: THOMPSON RG GOTTLIEB A ORGAN K KODA J KISICKI J KOLTERMAN OG

Citation: Rg. Thompson et al., PRAMLINTIDE - A HUMAN AMYLIN ANALOG REDUCED POSTPRANDIAL PLASMA-GLUCOSE, INSULIN, AND C-PEPTIDE CONCENTRATIONS IN PATIENTS WITH TYPE-2 DIABETES, Diabetic medicine, 14(7), 1997, pp. 547-555

Authors: THOMPSON RG GOTTLIEB AB ORGAN K KOLTERMAN OG

Citation: Rg. Thompson et al., THE HUMAN AMYLIN ANALOG (AC137) REDUCES GLUCOSE FOLLOWING SUSTACAL(R)IN PATIENTS WITH TYPE-II DIABETES, Diabetes, 44, 1995, pp. 127-127

Authors: KOLTERMAN O ORGAN K GOTTLIEB A

Citation: O. Kolterman et al., INTRAVENOUS (IV) INFUSION OF THE HUMAN AMYLIN ANALOG, AC-137, REDUCESPOSTPRANDIAL HYPERGLYCEMIA (PPH) IN SUBJECTS WITH TYPE-I DIABETES-MELLITUS RECEIVING ORAL NUTRIENTS BUT NOT IV GLUCOSE, Diabetes, 44, 1995, pp. 127-127